PK analyzes in RA patients displayed an evident trend toward higher clearance of adalimumab in the presence of anti-adalimumab antibodies and poorer clearance with an increase in age among patients in the age range ≥40 years ( Hyland et al., 2016 ; Puri et al., 2017 ; Hillson et al., 2018 ; von Richter et al., 2019 ).
← all excerpts
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects.
1
—
—